NO982055L - 2-alkylpyrrolidiner - Google Patents

2-alkylpyrrolidiner

Info

Publication number
NO982055L
NO982055L NO982055A NO982055A NO982055L NO 982055 L NO982055 L NO 982055L NO 982055 A NO982055 A NO 982055A NO 982055 A NO982055 A NO 982055A NO 982055 L NO982055 L NO 982055L
Authority
NO
Norway
Prior art keywords
alkylpyrrolidine
methylpyrrolidines
hydroxymethylpyrrolidine
dihydroxy
substituted
Prior art date
Application number
NO982055A
Other languages
English (en)
Other versions
NO982055D0 (no
Inventor
Karsten Lundgren
Palle Jakobsen
Marit Kristiansen
Leif Noerskov-Lauritsen
Lars Naerum
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO982055D0 publication Critical patent/NO982055D0/no
Publication of NO982055L publication Critical patent/NO982055L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

(2R,3R,4R)-3,4-dihydroksy-2- hydroksymetylpyrrolidin og andre sub- stituerte 2-metylpyrrolidiner kan an- vendes til behandling av sukkersyke.
NO982055A 1995-09-08 1998-05-06 2-alkylpyrrolidiner NO982055L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK99295 1995-09-08
PCT/DK1996/000373 WO1997009040A1 (en) 1995-09-08 1996-09-06 2-alkylpyrrolidines

Publications (2)

Publication Number Publication Date
NO982055D0 NO982055D0 (no) 1998-05-06
NO982055L true NO982055L (no) 1998-05-06

Family

ID=8099807

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982055A NO982055L (no) 1995-09-08 1998-05-06 2-alkylpyrrolidiner

Country Status (12)

Country Link
US (2) US5854272A (no)
EP (3) EP1040827A3 (no)
JP (2) JP3043430B2 (no)
CN (1) CN1202105A (no)
AT (1) ATE234092T1 (no)
AU (1) AU724003B2 (no)
CZ (1) CZ120398A3 (no)
DE (1) DE69626660T2 (no)
HU (1) HUP9901132A2 (no)
IL (1) IL124109A (no)
NO (1) NO982055L (no)
WO (1) WO1997009040A1 (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU724003B2 (en) * 1995-09-08 2000-09-07 Novo Nordisk A/S 2-alkylpyrrolidines
US5952363A (en) * 1997-03-04 1999-09-14 Novo Nordisk A/S Pyrrolidine compounds useful in the treatment of diabetes
WO1998040353A1 (en) * 1997-03-07 1998-09-17 Novo Nordisk A/S Novel heterocyclic compounds
AU2535700A (en) * 1999-02-12 2000-08-29 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
US6316489B1 (en) * 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
AU3147900A (en) * 1999-03-15 2000-10-04 Novo Nordisk A/S New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
EP1163217B1 (en) * 1999-03-15 2005-09-21 Novo Nordisk A/S New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
WO2001068095A1 (en) * 1999-05-24 2001-09-20 Abaron Biosciences, Inc. Glycosyltransferase inhibitors
US6043091A (en) * 1999-07-19 2000-03-28 Isis Pharmaceuticals Inc. Antisense modulation of liver glycogen phosphorylase expression
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6414163B1 (en) * 2000-08-02 2002-07-02 Board Of Trustees Of Michigan State University Process and intermediate compounds for the preparation of pyrrolidines
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
JP2006507359A (ja) * 2002-10-28 2006-03-02 ノボ・ノルデイスク・エー／エス 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
JP4486792B2 (ja) * 2003-06-12 2010-06-23 学校法人近畿大学 環状オニウム化合物およびグルコシダーゼ阻害剤
EP1670815A2 (en) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortin receptor agonists
ATE498404T1 (de) 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
JP4834840B2 (ja) 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
EP1758856A2 (en) 2004-05-04 2007-03-07 Novo Nordisk A/S Indole derivatives for the treatment of obesity
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
CN101137631A (zh) 2004-12-03 2008-03-05 转化技术制药公司 杂芳族葡糖激酶激活剂
KR100696187B1 (ko) 2005-05-03 2007-03-20 (주)리드젠 2-(2-아미노에틸)-1-메틸피롤리딘의 제조방법
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
US7915299B2 (en) 2006-11-15 2011-03-29 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
WO2010049678A2 (en) * 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
JP5645137B2 (ja) * 2009-11-11 2014-12-24 国立大学法人富山大学 食後過血糖改善剤、およびピロリジン型イミノ糖またはその塩
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
EP2552950A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
RU2609210C2 (ru) 2010-12-23 2017-01-31 Алектос Терапьютикс Инк. Селективные ингибиторы гликозидазы и их применение
JP2014510739A (ja) 2011-03-28 2014-05-01 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
EP2691407B1 (en) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9701693B2 (en) 2011-06-27 2017-07-11 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
EP2890676B1 (en) 2012-08-31 2018-12-05 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2890675A4 (en) 2012-08-31 2016-01-13 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
KR20150079711A (ko) 2012-10-31 2015-07-08 알렉토스 테라퓨틱스 인크. 글리코시다아제 저해제 및 이의 용도
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN106349141B (zh) * 2016-08-30 2020-10-27 中国科学院化学研究所 多羟基吡咯烷类化合物及其制备方法和应用
JP2020514365A (ja) 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス メラノコルチン４受容体に結合可能な二環式化合物
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
WO2025252661A1 (en) 2024-06-03 2025-12-11 Immunic Ag Reducing body weight and/or induction of satiety by triazolo compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1602744A (no) 1968-02-16 1971-01-18
JPS5346967A (en) 1976-10-08 1978-04-27 Kyowa Hakko Kogyo Co Ltd R-2-(beta-halogenoethyl)-1-methyl-pyrrolidine
JPS6058749B2 (ja) 1978-02-09 1985-12-21 日清製粉株式会社 光学活性ｎ‐メチル‐２‐ピロリジンエタノ−ルの製造法
JPS61118360A (ja) 1984-11-13 1986-06-05 Mitsubishi Chem Ind Ltd ピロリジン誘導体またはその塩
US4999360A (en) * 1987-12-21 1991-03-12 Monsanto Company Method of inhibiting virus
ES2086323T3 (es) * 1988-11-03 1996-07-01 Searle & Co Derivados del didesoxi-arabinitol como compuestos antiviricos.
US4973602A (en) * 1988-11-03 1990-11-27 G. D. Searle & Co. Antiviral compounds and a method of use thereas
US4876268A (en) * 1988-11-03 1989-10-24 G. D. Searle & Co. Antiviral compounds and use thereof
US4894388A (en) 1988-12-22 1990-01-16 Monsanto Company Glycosidase inhibitors and use thereof
EP0389723A1 (en) * 1989-03-29 1990-10-03 Merrell Dow Pharmaceuticals Inc. Novel alpha-glucosidase inhibitors
FR2648486B1 (fr) * 1989-06-16 1991-08-30 Gerland Sa Composition pour le traitement antifeutrant de la laine
EP0422307A1 (en) * 1989-10-10 1991-04-17 Merrell Dow Pharmaceuticals Inc. Novel alpha-glucosidase inhibitors
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
US5290948A (en) * 1990-09-17 1994-03-01 Mcneilab, Inc. Process for producing polyhydroxylated piperidines and pyrrolidines and compounds thereof
US5401645A (en) 1992-03-16 1995-03-28 Monsanto Company Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium
JPH0625157A (ja) 1992-07-13 1994-02-01 Taisho Pharmaceut Co Ltd ポリヒドロキシピロリジン誘導体類およびその製造方法
AU724003B2 (en) * 1995-09-08 2000-09-07 Novo Nordisk A/S 2-alkylpyrrolidines

Also Published As

Publication number Publication date
CN1202105A (zh) 1998-12-16
EP1040827A2 (en) 2000-10-04
IL124109A (en) 2001-10-31
US6451836B1 (en) 2002-09-17
AU724003B2 (en) 2000-09-07
EP1040827A3 (en) 2000-10-11
JP2000095686A (ja) 2000-04-04
JP3043430B2 (ja) 2000-05-22
DE69626660T2 (de) 2003-08-21
ATE234092T1 (de) 2003-03-15
NO982055D0 (no) 1998-05-06
DE69626660D1 (en) 2003-04-17
EP0884050A1 (en) 1998-12-16
CZ120398A3 (cs) 1998-12-16
HUP9901132A2 (hu) 1999-07-28
EP0858335A1 (en) 1998-08-19
EP0858335B1 (en) 2003-03-12
AU6785996A (en) 1997-03-27
WO1997009040A1 (en) 1997-03-13
JPH11503762A (ja) 1999-03-30
US5854272A (en) 1998-12-29
IL124109A0 (en) 1998-12-06

Similar Documents

Publication Publication Date Title
NO982055L (no) 2-alkylpyrrolidiner
ES2153337T1 (es) Inhibidores de raf-quinasa.
ES2159318T3 (es) Inhibidores de la proteina quinasa c.
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
MXPA02004666A (es) Gelatinas recombinantes.
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
BG63122B1 (bg) Съединения и методи за лечение на рак
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
DE69425433D1 (de) Getränke-stabilisierungssystem
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
BG102644A (bg) Подобрени концентрирани инжекционни и инфузионниразтвори за интравазално прилагане
CA2304657A1 (en) Treatment of conduct disorder
BG101392A (en) Method of treating diabetes mellitus using kgf
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
NO980251L (no) Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse
IL90414A (en) Combination of angiotensin converting enzyme inhibitors with potassium channel modulators and use thereof in pharmaceuticals
NO983802L (no) Benzothiofener, formuleringer inneholdende samme og fremgangsmåter
BG100248A (bg) Инхибитори на скваленсинтетаза
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
PT633928E (pt) Microrganismos processo de preparacao e utilizacao
EA199800819A1 (ru) Способ лечения биполярного расстройства
FR2700336B1 (fr) Succinimides substituées, leur procédé de préparation et leur application comme inhibiteur de corrosion.
DK1032580T3 (da) Fremgangsmåde til N-desmethylering af erythromyciner og derivater deraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application